Drug intelligence / Profile preview

SIBP-04

Development stage: Phase 3
Lead developer: Shanghai Institute of Biological Products
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SIBP-04 is a biosimilar of bevacizumab (Avastin®), a recombinant, fully human, monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels. It is being developed by Shanghai Institute of Biological Products.

Other names: Bevacizumab biosimilar SIBP-04

Targets

VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on SIBP-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIBP-04.

Explore the full profile